Tianan Fang

USPTO Granted Patents = 24 (Patent Applications = 5)

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 16 (Patent Applications = 15)

Average Co-Inventor Count = 10.4

ph-index = 5

Forward Citations = 112(Granted Patents)

Location History:

Levittown, PA (US) (2008 - 2018)
Newtown, PA (US) (2016 - 2023)

Company Filing History:

23 out of 3,681

Bristol-myers Squibb Compnay

patents

1 out of 7

Syngene International Limited

where one patent can have more than one assignee

Years Active: 2008-2025

where 'Filed Patents' based on already Granted Patents

24 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12428421 - Pyrimidinones as factor XIA inhibitors (2025-09-30),

2. 12404274 - Macrocycles as factor xia inhibitors (2025-09-02),

3. RE49352 - Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists (2023-01-02),

4. 11352345 - Cyclohexyl acid pyrazole azoles as LPA antagonists (2022-06-07),

5. 11319315 - Cyclohexyl acid triazole azoles as LPA antagonists (2022-05-03),

6. 11267800 - Cyclohexyl acid triazole azines as LPA antagonists (2022-03-08),

7. 11136327 - Macrocycles as factor XIA inhibitors (2021-10-05),

8. 11053247 - Pyrimidinones as factor XIA inhibitors (2021-07-06),

9. 11007180 - Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists (2021-05-18),

10. 10576062 - Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists (2020-03-03),

11. 10487086 - Macrocycles as factor XIa inhibitors (2019-11-26),

12. 10336754 - Pyrimidinones as factor XIa inhibitors (2019-07-02),

13. 10273236 - Macrocyclic factor XIa inhibitors bearing heterocyclic groups (2019-04-30),

14. 10071078 - Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists (2018-09-11),

15. 9951071 - Dihydropyridone P1 as factor XIa inhibitors (2018-04-24),

Title: The Innovative Contributions of Tianan Fang

Introduction

Tianan Fang, based in Newtown, PA, has made significant strides in the field of pharmaceutical sciences through his innovative inventions. With an impressive portfolio of 22 patents, Fang's work primarily focuses on selective LPA receptor inhibitors, showcasing his expertise and creativity in medicinal chemistry.

Latest Patents

Among his most recent patents, Fang has developed several notable compounds. One such invention is related to carbamoyloxymethyl triazole cyclohexyl acids, which are identified as LPA antagonists. This invention provides a unique formulation of compounds that can serve as selective inhibitors for LPA receptors. Another of his pioneering works involves cyclohexyl acid pyrazole azoles, also aimed at being LPA antagonists. This invention similarly details a formula for compounds that serve as selective LPA receptor inhibitors, further emphasizing Fang's commitment to enhancing therapeutic options in medicine.

Career Highlights

Tianan Fang's career includes impactful tenures at renowned companies like Bristol-Myers Squibb Company and Syngene International Limited. His experiences in these organizations highlight his capability in translating scientific knowledge into practical applications that advance the pharmaceutical industry.

Collaborations

Throughout his career, Fang has collaborated with esteemed colleagues including James R. Corte and Donald J. P. Pinto. These partnerships have not only enriched his professional journey but have also contributed to the broader scientific community, underscoring the importance of teamwork in driving innovations.

Conclusion

In conclusion, Tianan Fang's contributions to the field of pharmaceuticals through his extensive patent portfolio and innovative inventions are noteworthy. His work not only reflects his dedication as an inventor but also showcases the potential for significant advancements in therapeutic solutions. With a strong foundation and notable collaborations, Fang continues to be a leading figure in the development of novel medicinal compounds.

This text is generated by artificial intelligence and may not be accurate.